365 related articles for article (PubMed ID: 27621596)
1. Anti-inflammatory drugs for Duchenne muscular dystrophy: focus on skeletal muscle-releasing factors.
Miyatake S; Shimizu-Motohashi Y; Takeda S; Aoki Y
Drug Des Devel Ther; 2016; 10():2745-58. PubMed ID: 27621596
[TBL] [Abstract][Full Text] [Related]
2. Alterations in Notch signalling in skeletal muscles from mdx and dko dystrophic mice and patients with Duchenne muscular dystrophy.
Church JE; Trieu J; Chee A; Naim T; Gehrig SM; Lamon S; Angelini C; Russell AP; Lynch GS
Exp Physiol; 2014 Apr; 99(4):675-87. PubMed ID: 24443351
[TBL] [Abstract][Full Text] [Related]
3. Inositol 1,4,5-trisphosphate (IP3)-dependent Ca2+ signaling mediates delayed myogenesis in Duchenne muscular dystrophy fetal muscle.
Farini A; Sitzia C; Cassinelli L; Colleoni F; Parolini D; Giovanella U; Maciotta S; Colombo A; Meregalli M; Torrente Y
Development; 2016 Feb; 143(4):658-69. PubMed ID: 26884398
[TBL] [Abstract][Full Text] [Related]
4. Skeletal muscle secretome in Duchenne muscular dystrophy: a pivotal anti-inflammatory role of adiponectin.
Lecompte S; Abou-Samra M; Boursereau R; Noel L; Brichard SM
Cell Mol Life Sci; 2017 Jul; 74(13):2487-2501. PubMed ID: 28188344
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological prospects in the treatment of Duchenne muscular dystrophy.
Ruegg UT
Curr Opin Neurol; 2013 Oct; 26(5):577-84. PubMed ID: 23995279
[TBL] [Abstract][Full Text] [Related]
6. Morpholinos and their peptide conjugates: therapeutic promise and challenge for Duchenne muscular dystrophy.
Moulton HM; Moulton JD
Biochim Biophys Acta; 2010 Dec; 1798(12):2296-303. PubMed ID: 20170628
[TBL] [Abstract][Full Text] [Related]
7. Mitochondria and Reactive Oxygen Species: The Therapeutic Balance of Powers for Duchenne Muscular Dystrophy.
Casati SR; Cervia D; Roux-Biejat P; Moscheni C; Perrotta C; De Palma C
Cells; 2024 Mar; 13(7):. PubMed ID: 38607013
[TBL] [Abstract][Full Text] [Related]
8. Intravenous infusion of an antisense oligonucleotide results in exon skipping in muscle dystrophin mRNA of Duchenne muscular dystrophy.
Takeshima Y; Yagi M; Wada H; Ishibashi K; Nishiyama A; Kakumoto M; Sakaeda T; Saura R; Okumura K; Matsuo M
Pediatr Res; 2006 May; 59(5):690-4. PubMed ID: 16627883
[TBL] [Abstract][Full Text] [Related]
9. Mechanical stress activates the nuclear factor-kappaB pathway in skeletal muscle fibers: a possible role in Duchenne muscular dystrophy.
Kumar A; Boriek AM
FASEB J; 2003 Mar; 17(3):386-96. PubMed ID: 12631578
[TBL] [Abstract][Full Text] [Related]
10. Altered ROS production, NF-κB activation and interleukin-6 gene expression induced by electrical stimulation in dystrophic mdx skeletal muscle cells.
Henríquez-Olguín C; Altamirano F; Valladares D; López JR; Allen PD; Jaimovich E
Biochim Biophys Acta; 2015 Jul; 1852(7):1410-9. PubMed ID: 25857619
[TBL] [Abstract][Full Text] [Related]
11. Duchenne muscular dystrophy: Focus on arachidonic acid metabolites.
Hoxha M
Biomed Pharmacother; 2019 Feb; 110():796-802. PubMed ID: 30554118
[TBL] [Abstract][Full Text] [Related]
12. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species.
Whitehead NP; Yeung EW; Allen DG
Clin Exp Pharmacol Physiol; 2006 Jul; 33(7):657-62. PubMed ID: 16789936
[TBL] [Abstract][Full Text] [Related]
13. Improvement of endurance of DMD animal model using natural polyphenols.
Sitzia C; Farini A; Colleoni F; Fortunato F; Razini P; Erratico S; Tavelli A; Fabrizi F; Belicchi M; Meregalli M; Comi G; Torrente Y
Biomed Res Int; 2015; 2015():680615. PubMed ID: 25861640
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic effects of exon skipping and losartan on skeletal muscle of mdx mice.
Lee EJ; Kim AY; Lee EM; Lee MM; Min CW; Kang KK; Park JK; Hwang M; Kwon SH; Tremblay JP; Jeong KS
Pathol Int; 2014 Aug; 64(8):388-96. PubMed ID: 25143127
[TBL] [Abstract][Full Text] [Related]
15. Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy.
Lawler JM
J Physiol; 2011 May; 589(Pt 9):2161-70. PubMed ID: 21486793
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic potential of PEGylated insulin-like growth factor I for skeletal muscle disease evaluated in two murine models of muscular dystrophy.
Gehrig SM; van der Poel C; Hoeflich A; Naim T; Lynch GS; Metzger F
Growth Horm IGF Res; 2012 Apr; 22(2):69-75. PubMed ID: 22424862
[TBL] [Abstract][Full Text] [Related]
17. Deubiquitinating enzyme A20 negatively regulates NF-κB signaling in skeletal muscle in mdx mice.
Charan RA; Hanson R; Clemens PR
FASEB J; 2012 Feb; 26(2):587-95. PubMed ID: 22012122
[TBL] [Abstract][Full Text] [Related]
18. Drug Discovery of Therapies for Duchenne Muscular Dystrophy.
Blat Y; Blat S
J Biomol Screen; 2015 Dec; 20(10):1189-203. PubMed ID: 25975656
[TBL] [Abstract][Full Text] [Related]
19. [Genetic Diagnosis and Molecular Therapies for Duchenne Muscular Dystrophy].
Takeshima Y
Rinsho Byori; 2015 Oct; 63(10):1194-201. PubMed ID: 26897856
[TBL] [Abstract][Full Text] [Related]
20. Anti-Inflammatory and General Glucocorticoid Physiology in Skeletal Muscles Affected by Duchenne Muscular Dystrophy: Exploration of Steroid-Sparing Agents.
Herbelet S; Rodenbach A; Paepe B; De Bleecker JL
Int J Mol Sci; 2020 Jun; 21(13):. PubMed ID: 32605223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
